Monoclonal Antibodies to CGRP or Its Receptor for Migraine Prevention

Migraine is a highly prevalent, disabling neurological disease that significantly affects patients’ quality of life. There are significant unmet needs in the treatment of migraine, which is often misdiagnosed and undertreated. Monoclonal antibodies targeting the calcitonin gene-related peptide pathw...

Full description

Saved in:
Bibliographic Details
Published in:Journal for nurse practitioners 2019-11, Vol.15 (10), p.717-724.e1
Main Authors: Moriarty, Maureen, Mallick-Searle, Theresa, Barch, Carol A., Oas, Kim
Format: Article
Language:English
Subjects:
Antibodies
calcitonin gene-related peptide (CGRP)
chronic
episodic
Headaches
Immunoglobulins
Ligands
Migraine
Misdiagnosis
Monoclonal antibodies
Nervous system
Neuropeptides
Pain
Patients
Peptides
Prevention
Pruritus
Quality of life
Questionnaires
Treatment needs
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Migraine is a highly prevalent, disabling neurological disease that significantly affects patients’ quality of life. There are significant unmet needs in the treatment of migraine, which is often misdiagnosed and undertreated. Monoclonal antibodies targeting the calcitonin gene-related peptide pathway, either the ligand or its receptor, are promising new drugs for the prevention of episodic and chronic migraine. We review the current evidence for these new monoclonal antibodies. •Migraine is a complex, debilitating neurological disorder affecting millions of people worldwide.•Migraine is often undertreated, and adherence to preventive therapies has been poor.•MAbs targeting CGRP or its receptor are promising new drugs for the prevention of migraine.•Erenumab, fremanezumab, galcanezumab, and eptinezumab have shown efficacy in clinical trials.•These 4 new mAbs have demonstrated good safety and tolerability profiles.
ISSN:1555-4155
1878-058X
DOI:10.1016/j.nurpra.2019.07.009